Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Update

Vivani Medical, Inc. (NASDAQ:VANI) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 401,264 shares, an increase of 87.4% from the January 15th total of 214,164 shares. Currently, 1.0% of the shares of the company are short sold. Based on an average daily trading volume, of 771,804 shares, the short-interest ratio is currently 0.5 days. Based on an average daily trading volume, of 771,804 shares, the short-interest ratio is currently 0.5 days. Currently, 1.0% of the shares of the company are short sold.

Insider Activity at Vivani Medical

In other news, Director Gregg Williams acquired 1,351,351 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was bought at an average price of $1.48 per share, with a total value of $1,999,999.48. Following the completion of the acquisition, the director directly owned 27,915,460 shares of the company’s stock, valued at approximately $41,314,880.80. The trade was a 5.09% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired a total of 4,826,881 shares of company stock valued at $5,962,104 over the last three months. Insiders own 46.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Marshall Wace LLP bought a new position in Vivani Medical in the 4th quarter worth approximately $174,000. Geode Capital Management LLC increased its holdings in Vivani Medical by 29.6% in the 4th quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock valued at $568,000 after acquiring an additional 105,398 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after purchasing an additional 53,127 shares in the last quarter. Jane Street Group LLC purchased a new stake in Vivani Medical in the 4th quarter worth $60,000. Finally, Panagora Asset Management Inc. bought a new position in shares of Vivani Medical during the 2nd quarter valued at about $25,000. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Vivani Medical Stock Up 0.9%

NASDAQ VANI opened at $1.18 on Friday. Vivani Medical has a 52 week low of $0.91 and a 52 week high of $1.92. The company has a market capitalization of $92.24 million, a P/E ratio of -2.62 and a beta of 3.11. The stock’s 50-day moving average price is $1.34 and its 200-day moving average price is $1.37.

Vivani Medical (NASDAQ:VANI) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. Research analysts anticipate that Vivani Medical will post -0.41 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on VANI. Zacks Research raised Vivani Medical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 12th. Wall Street Zen upgraded shares of Vivani Medical to a “sell” rating in a research note on Saturday, November 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $4.00.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.